AbCellera BiologicsABCL +10.81%59 PB Ratio is 2.39 as of Jun. 27, 2026, which is 50% above its 10-year median of 1.59. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, AbCellera Biologics ranks better than 59.42% on this metric.
AbCellera Biologics Inc stock PB Ratio (=2.39) is close to 3-year high of 2.39.
The historical rank and industry rank for AbCellera Biologics's PB Ratio or its related term are showing as below:
ABCL'
s PB Ratio Range Over the Past 10 Years
Min: 0.57 Med: 1.59 Max: 175.3
Current: 2.39
During the past 8 years, AbCellera Biologics's highest PB Ratio was 175.30. The lowest was 0.57. And the median was 1.59.
ABCL's PB Ratio is ranked better than 59.42% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ABCL: 2.39
During the past 12 months, AbCellera Biologics's average Book Value Per Share Growth Rate was -10.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.30% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of AbCellera Biologics was 654.70% per year. The lowest was -9.20% per year. And the median was 8.70% per year.
Back to Basics: PB Ratio
AbCellera Biologics (NAS:ABCL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
AbCellera Biologics PB Ratio Related Terms
AbCellera Biologics PB Ratio Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AbCellera Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
AbCellera Biologics (ABCL) has a PB Ratio of 2.39 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AbCellera Biologics and its competitors. This is 50% above median its historical median of 1.59. Over the past decade, AbCellera Biologics' PB Ratio has ranged from 0.57 to 175.30. According to the industry distribution chart, AbCellera Biologics ranks #500 out of 1232 companies in the Biotechnology industry, placing it in the top 40.6%.
Is AbCellera Biologics' PB Ratio too high?
AbCellera Biologics' current PB Ratio of 2.39 is 50% above median its 10-year median of 1.59. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 175.30. The Biotechnology industry median PB Ratio is 2.80. AbCellera Biologics' value of 2.39 is 14.6% below this industry median. Based on the distribution chart, AbCellera Biologics ranks #500 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' PB Ratio compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #500 out of 1232 companies for PB Ratio. This puts AbCellera Biologics in the upper half of its industry. The industry median PB Ratio is 2.80. AbCellera Biologics' value of 2.39 is 14.6% below this benchmark. Historically, AbCellera Biologics' own PB Ratio has ranged from 0.57 to 175.30 over the past decade. While the company's 10-year median is 1.59 vs. the industry median of 2.80, AbCellera Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current PB Ratio of 2.39 is 14.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current PB Ratio is 2.39, which is 50% above median its own 10-year median of 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current PB Ratio is 2.39, which is 50% above median its 10-year median of 1.59 and 14.6% below the Biotechnology industry median of 2.80. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current PB Ratio is 2.39 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
PB Ratio: 2.39 (50% above median its 10-year median of 1.59)
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
Industry Position: 14.6% below the Biotechnology median (#500 of 1232)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
